
Manager
sector
Healthcare
regional split
Europe
vintage
status
Portfolio
category
Innovative
General Atlantic 2021
General Atlantic
Verdiva Bio
Co-invested company
A company specializing in the treatment of obesity
Founded in 2024, Verdiva Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for obesity and cardiometabolic disorders.
2024
creation date
+600
employees
3
products in development
2
country
Data as at
13/8/26
*Source: Public data from companies’ websites and social media accounts. For more up-to-date information, we invite our investors to view the report made available on their space.

Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing next-generation treatments for obesity and cardio-metabolic disorders.
Its portfolio includes oral and injectable therapies, currently in phase 2 clinical development. This treatment showed promising efficacy in a Phase 1 trial in Australia.
Company news
Company videos
No items found.
Discover the new Vintage Altaroc Odyssey

Discover the Vintage Altaroc Horizon

